Skip to Content

Disclaimer

Disclaimer
MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

International Parkinson and Movement Disorder Society
Main Content

Anti-inflammatory drugs use impacts the risk of developing PD in LRRK2 mutation carriers

November 09, 2020
Episode:35
Dr. Marta San Luciano shares the main findings of the recently published article on the impact of non-steroidal anti-inflammatory drugs use on the risk of developing PD in a large LRRK2 mutation carriers cohort. Read the article
Special thank you to:Dr. Marta San Luciano
Host(s):
Michele Matarazzo, MD 

Pacific Parkinson’s Research Centre, The University of British Columbia

Vancouver, BC, Canada

We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including mds.movementdisorders.org and mds.execinc.com. This cookie policy only covers the primary movementdisorders.org and mdscongress.org domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice